Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6622078 | 1.00 | ESR1 (0.44) | ESR1ESR2HCAR2CA12AKR1B10 | |
| SCHEMBL6616683 | 0.82 | CYSLTR2 (0.40) | ESR1CA12AKR1B10CA1CA2 | |
| SCHEMBL5738247 | 0.80 | TPMT (0.61) | CA12CA1CA2CA3CA4 | |
| SCHEMBL767486 | 0.79 | HCAR2 (0.65) | ESR1ESR2HCAR2CA12AKR1B10 | |
| SCHEMBL557028 | 0.79 | HCAR2 (0.65) | ESR1ESR2HCAR2CA12AKR1B10 | |
| SCHEMBL5735738 | 0.76 | MAOB (0.54) | ESR1HDAC1HDAC8SRD5A2KDM4E | |
| SCHEMBL6617928 | 0.76 | MAOB (0.54) | ESR1HDAC1HDAC8SRD5A2KDM4E | |
| SCHEMBL5734568 | 0.72 | TPMT (0.46) | CA12CA1CA2CA6CA9 | |
| SCHEMBL5735238 | 0.70 | CA2 (0.41) | CA12CA1CA2CA3CA6 | |
| SCHEMBL713717 | 0.70 | HCAR2 (0.81) | ESR1ESR2HCAR2CA12AKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399156-B1 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS (AN) | 2006-11-22 | — | — | EP | claimed |
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | LABORATOIRES SERONO SA (CH) | 2004-11-04 | — | — | US | claimed |
| EP-1399156-B1 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS (AN) | 2006-11-22 | — | — | EP | disclosed |
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | LABORATOIRES SERONO SA (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1399156-A2 | ALKYLIDENE PIRAZOLIDINEDIONE DERIVATIVES AND THEIR USE FOR TREATING DIABETES AND OBESITY | Applied Research Systems ARS Holding N.V. (AN) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002102359-A2 | ALKYLIDENE PYRAZOLIDINEDIONE DERIVATIVES AND USE FOR TREATING DIABETES AND OBESITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220188-A1 | Alkylidene pyrazolidinedione derivatives | G6PC1, PPM1D, PTPRS | ESR1 2024/4885ESR2 1656/4885HCAR2 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.